

Polyphor Ltd

PEM - a New Class of Drugs

Polyphor is a Swiss biotech company providing innovative products with high therapeutic benefit to the patient and high quality drug discovery support to its pharmaceutical industry partners.


Innovation in drug discovery

In the 13 years since its foundation, Polyphor has established a solid track record of innovative contributions to drug discovery using its proprietary Protein Epitope Mimetics (PEM) Technology. PEM Technology allows Polyphor to discover fully synthetic "PEMdrugs" with powerful therapeutic effects. Most recently, Polyphor demonstrated the power of its PEM Technology through the discovery of a whole new class of antibiotics – a once in 20 years scientific achievement!

Protein Epitope Mimetics (PEM) – a new class of drugs

- PEM are medium-sized, fully synthetic, structurally well-defined molecules
- PEM modulate protein-protein interactions very effectively and in a highly selective manner
- PEM Technology enables efficient optimization of the pharmacological properties of PEMdrugs
- Straightforward, highly automated production at reasonable costs

PEMdrugs are functional mini-mimizations of proteins



Polyphor has validated its PEM Technology multiple times. PEMdrugs have been shown to interfere with complex protein-protein interactions in a highly selective way. Polyphor's most advanced candidate POL6326, currently in clinical Phase II trials, demonstrates that PEM Technology can provide drugs that are safe and efficacious in man.

PEMdrug pipeline

POL6326 – a very potent, versatile and well-tolerated CXCR4 inhibitor

POL6326 is currently in Phase II clinical studies for blood stem cell transplantation. It has further potential in the treatment of leukemia patients and tissue repair (e.g. inflammation, heart attack, renal failure, diabetes) and in the treatment of asthma.

POL7080 – a highly selective antibiotic using a novel mechanism of action

POL7080 is an antibiotic PEMdrug candidate poised to enter the clinic that acts against the dangerous multi-drug resistant strains of *Pseudomonas aeruginosa*.

POL6014 – a highly selective protease inhibitor targeted to pulmonary delivery

POL6014 is a highly potent and selective inhibitor of the enzyme elastase. It has been optimized to treat pulmonary diseases such as Chronic Obstructive Pulmonary Disease, primarily associated with cigarette smoking. It can be administered to the lungs while systemic exposure remains low.

PEMfinder® collaborations with partners in the pharmaceutical industry

Polyphor offers its pharma partners access to PEM Technology through PEMfinder® collaborations. In this way, partners can exclusively select the therapeutic targets to which PEM Tech-

nology will be applied. Co-founder and CEO, Dr. Jean-Pierre Obrecht notes that "such PEMfinder® collaborations are an ideal starting point for more strategic alliances which allow us to broadly and rapidly exploit the full potential of PEM Technology."

Globally connected and headquartered in Allschwil/Basel

Polyphor is an internationally focused biotech company that has established a wide network of partnerships with pharma companies, CROs and universities in Europe, the USA and Japan. Headquartered in Allschwil, near Basel, Polyphor is located within one of Europe's most dynamic and outward looking life science clusters. Dr. Jean-Pierre Obrecht emphasizes, "Polyphor has selected Allschwil as home base because the location provides an excellent environment for drug discovery. Supportive authorities, access to a rich pool of skilled scientists and high quality of life attract biotech startups and global players alike."

Further expansion in Basel

In 2008, Polyphor combined all of its operations into a new research building, which was built to Polyphor's specific needs and which provides room for further expansion. Polyphor plans to further develop and strengthen its home base in Basel and to expand the portfolio of PEMdrug candidates, both on its own and together with its Pharma partners.



Hegenheimermattweg 125

CH- 4123 Allschwil

Phone: + 41 61 567 16 00 - Fax: + 41 61 567 16 01

www.polyphor.com